×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARWR – arrowhead pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARWR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/6
12:22 am
arwr
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... [Yahoo! Finance]
2/5
08:28 pm
arwr
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]
2/5
04:05 pm
arwr
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
Low
Report
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
2/3
08:41 pm
arwr
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
Medium
Report
Why Arrowhead Pharmaceuticals (ARWR) Is Up 7.8% After Launching Its First Dual-Gene RNAi Trial [Yahoo! Finance]
2/3
09:29 am
arwr
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
Medium
Report
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million [Yahoo! Finance]
1/27
07:42 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia [Yahoo! Finance]
1/27
07:30 am
arwr
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Low
Report
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
1/23
05:06 am
arwr
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Medium
Report
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
2/5/2026
04:05 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
-0.2%
arrowhead pharmaceuticals, inc.
11/25/2025
04:00 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
23.3%
arrowhead pharmaceuticals, inc.
8/7/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
MISS
Report
2.2%
arrowhead pharmaceuticals, inc.
5/12/2025
04:01 pm
ARWR
arrowhead pharmaceuticals, inc.
BEAT
Report
9.4%
arrowhead pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/5
04:07 pm
arwr
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
Low
Report
Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
2/5
04:05 pm
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
Low
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
1/27
06:02 am
arwr
Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26
Low
Report
Form ARS ARROWHEAD PHARMACEUTICAL For: Jan 26
1/27
06:00 am
arwr
Form DEFA14A ARROWHEAD PHARMACEUTICAL
Low
Report
Form DEFA14A ARROWHEAD PHARMACEUTICAL
1/27
06:00 am
arwr
Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26
Low
Report
Form DEF 14A ARROWHEAD PHARMACEUTICAL For: Jan 26
1/21
12:32 pm
arwr
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A ARROWHEAD PHARMACEUTICAL Filed by: BlackRock, Inc.
1/12
05:01 pm
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 12
Low
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 12
1/9
06:02 am
arwr
Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 07
Low
Report
Form 8-K ARROWHEAD PHARMACEUTICAL For: Jan 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/18
Bragar Eagel & Squire is Investigating Certain Officers and Directors of comScore, Mammoth Energy, AMC Entertainment, and Arrowhead Pharmaceuticals and Encourages Investors to Contact the Firm
23.9%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
11/25 Form 8-K ARROWHEAD PHARMACEUTICAL For: Nov 25 19.2%
12/2 Form 424B5 ARROWHEAD PHARMACEUTICAL 12.5%
3/19 Form 8-K ARROWHEAD PHARMACEUTICAL For: Mar 14 9.3%
11/25 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at Robert W. Baird from a "neutral" rating to an "outperform" rating. 8.8%
8/5 Form 8-K ARROWHEAD PHARMACEUTICAL For: Aug 05 6.8%
4/20 Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Incredible 2370% Share Price Run Shows What Is Possible With Stocks [Yahoo! Finance News] 6.4%
11/7 Form 4 ARROWHEAD PHARMACEUTICAL For: Nov 05 Filed by: Myszkowski Kenneth Allen 6.3%
5/8 Q2/2019 3/31/2019 EPS 0.240 ZacksConsensus 0.220 ActVsEst 0.020 - Beat 6.1%
8/19 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at B. Riley from $32.00 to $46.00. They now have a "buy" rating on the stock. 5.4%
TOP News Decliners
3/15
Is Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Salary Justified? [Yahoo! Finance News]
-16.8%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
2/6 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) had its price target raised by analysts at Cantor Fitzgerald from $50.00 to $55.00. They now have a "neutral" rating on the stock. -13.5%
12/2 3 Soaring Biotech Stocks to Watch in December [The Motley Fool] -13.3%
1/21 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) is now covered by analysts at Svb Leerink Llc. They set an "underperform" rating and a $32.00 price target on the stock. -10.5%
3/9 Why Arrowhead Pharmaceuticals Shares Dropped 15% in February [The Motley Fool] -7.5%
4/29 Form 4 ARROWHEAD PHARMACEUTICAL For: Apr 27 Filed by: GIVEN BRUCE D -7.4%
10/23 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was given a new $46.00 price target on by analysts at B. Riley. They now have a "buy" rating on the stock. -7.0%
8/22 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -6.9%
6/27 Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) was downgraded by analysts at Cantor Fitzgerald from an "overweight" rating to a "neutral" rating. -6.8%
12/20 Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease -6.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: